Bench International > blog new (Page 2)

“The Leading “Edge”

By DeeDee Deman - What defines a leading edge company in today’s tumultuous Pharma world?  It’s a company that steps up to define, “Courage.” Edge Therapeutics has placed its company’s bets on changing the course of brain trauma, simultaneously redefining, “Courageous.” Bench is honored to have...

“I Rest My Case!”

By DeeDee DeMan - Looking at the 2016 “report card,” on FDA approvals reinforces why we all need a knowledgeable champion like Scott Gottlieb, as FDA Commissioner. We’ve known for a few months now that 2016 was going to be a disappointing year for new drug approvals....

The Future of Drug Discovery

By Kimberly Plessala. - On the topic of artificial intelligence, I for one, tend towards the Hollywood version. Where machines eventually deciding the human race is such an imperfect system fraught with disease and intellectual thresholds that the only sensible solution is to eliminate us....

Advances in Alzheimer’s Disease

By Gail Rosenblum - Advances are being made globally in the area of Alzheimer’s disease and related dementia disorders, and Bench International has been privileged to work extensively in this field, partnering most recently with Chase Pharmaceuticals, Axovant Sciences and Bionomics Limited. Designated in 1983 by...